Polycystic Kidney, Autosomal Dominant Clinical Trial
Official title:
The Effect of High and Low Sodium Intake on Urinary Aquaporin-2 in Autosomal Dominant Polycystic Kidney Disease, During Basal Conditions and After Hypertonic Saline Infusion.
The aim of the study is to test the following hypotheses:
1. that the function and/or regulation of AQP2 and /or ENaC in the principal cells is
abnormal in autosomal dominant polycystic kidney disease.
2. if an abnormal function of the principal cells is present in autosomal dominant
polycystic kidney disease, this will become more pronounced at high and low sodium
intake.
Recruitment:
The patients with ADPKD are recruited from the Outpatient Nephrology Clinic of the Department
of Medicine, Holstebro Hospital (Holstebro, Denmark). The control subjects are recruited by
advertising in public institutions and private companies.
Number of Subjects:
A difference in u-AQP2CR of 40 ng/mmol is considered the minimal relevant difference. A
sample size of 10 subjects, who can be evaluated, has 80% power to detect this difference
assuming a level of significance of 5% and an SD of 30 ng/mmol. Because a few subjects are
expected to drop out, 14-15 subjects will be included in each group.
Experimental Procedure Before the Study Day:
Five days before the study day, the subjects collect a standardized, HS (300 mmol
sodium/day/17.5 g salt/day) or LS (30 mmol sodium/day/1.8 g salt/day), 4-day diet from the
hospital kitchen. Depending on the individually estimated energy requirement, the
participants are given either a diet of 8,000 or 11,000 kJ/day. The energy distribution is
55% carbohydrates, 15% proteins, and 30% lipids. The 4-day diet is started the following
morning. The fluid intake is also standardized during the 4 days. The subjects are asked to
drink exactly 250 ml/1,000 kJ/day and to abstain from coffee, tea, and alcoholic beverages.
The subjects are instructed to keep their physical activity unchanged during the two
experiments and to abstain from hard training. The subjects have to collect their urine for
24 h the day before the study day.
Experimental Procedure on the Study Day:
On the study day, the subjects are asked to drink 175 ml of water every 30 min from 7:00 AM.
The subjects arrive at the department at 8:00 AM. Peripheral iv lines are inserted into the
antecubital veins of both forearms, one for infusion of 51Cr-EDTA and hypertonic saline, and
one for withdrawal of blood samples. The subjects will be kept in the supine position from
8:00 AM to 1:30 PM except during voiding, which will take place in the sitting or standing
position. At 8:30 AM, a priming dose of 51Cr-EDTA is administered, followed by sustained
infusion. After 60 min of equilibration, the study will continue with five clearance periods,
the first two of 30-min duration (P1-P2), the last three of 60-min duration (P3-P5). The first
two clearance periods are baseline periods. At 10:30 AM, 7 ml/kg of 3% saline is given over
30 min. Blood pressure and heart rate are measured every 30 min from 9:30 AM to 1:30 PM.
Urine is collected in each clearance period and analyzed for sodium, osmolality, u-AQP2,
u-ENaC-betaCR, u-cAMP, u-PGE2, and 51CrEDTA. Blood samples will be drawn every 30 min from
9:30 AM to 10:30 AM and every hour from 11:30 AM to 1:30 PM, and will be analyzed for sodium,
osmolality, and 51Cr-EDTA. In addition, analysis of p-AVP, p-Renin, p-ANG II, p-Aldo, p-ANP,
and p-BNP will be performed from blood samples drawn at 10:30 AM, 11:30 AM, 12:30 PM, and
1:30 PM.
Statistics:
Statistical analyses will be performed using SPSS version 15 (SPSS, Chicago, IL). Single
baseline values are obtained by taking the weighted average of the measurements from the two
baseline periods. The baseline values of the two groups will be compared by Student's t-test.
The baseline values during HS and LS intake will be compared by paired samples t-tests. The
investigators will use the "General Linear Model Repeated Measures" procedure in SPSS with
time as the within-subject factor and group as the between-subject factor to compare the
effect variables in patients and controls. The changes in response to the hypertonic saline
infusion in each group will be analyzed with the General Linear Model Repeated Measures
procedure with time as the within-subject factor and paired samples t-tests with Bonferroni
correction as post hoc tests. P values Recruitment The patients with ADPKD will be recruited
from the Outpatient Nephrology Clinic of the Department of Medicine, Holstebro Hospital
(Holstebro, Denmark). The control subjects will be recruited by advertising in public
institutions and private companies.
Number of Subjects A difference in u-AQP2CR of 40 ng/mmol is considered the minimal relevant
difference. A sample size of 10 subjects, who could be evaluated, has 80% power to detect
this difference assuming a level of significance of 5% and an SD of 30 ng/mmol. Because a few
subjects are expected to drop out, 14-15 subjects will be included in each group.
Experimental Procedure Before the Study Day Five days before the study day, the subjects will
collect a standardized, HS (300 mmol sodium/day/17.5 g salt/day) or LS (30 mmol
sodium/day/1.8 g salt/day), 4-day diet from the hospital kitchen. Depending on the
individually estimated energy requirement, the participants will be given either a diet of
8,000 or 11,000 kJ/day. The energy distribution will be 55% carbohydrates, 15% proteins, and
30% lipids. The 4-day diet will start the following morning. The fluid intake is also
standardized during the 4 days. The subjects are asked to drink exactly 250 ml/1,000 kJ/day
and to abstain from coffee, tea, and alcoholic beverages. The subjects will be instructed to
keep their physical activity unchanged during the two experiments and to abstain from hard
training. The subjects have to collect their urine for 24 h the day before the study day.
Experimental Procedure on the Study Day On the study day, the subjects are asked to drink 175
ml of water every 30 min from 7:00 AM. The subjects arrive at the department at 8:00 AM.
Peripheral iv lines will be inserted into the antecubital veins of both forearms, one for
infusion of 51Cr-EDTA and hypertonic saline, and one for withdrawal of blood samples. The
subjects will be kept in the supine position from 8:00 AM to 1:30 PM except during voiding,
which will take place in the sitting or standing position. At 8:30 AM, a priming dose of
51Cr-EDTA is administered, followed by sustained infusion. After 60 min of equilibration, the
study will continue with five clearance periods, the first two of 30-min duration (P1-P2), the
last three of 60-min duration (P3-P5). The first two clearance periods are baseline periods.
At 10:30 AM, 7 ml/kg of 3% saline is given over 30 min. Blood pressure and heart rate will be
measured every 30 min from 9:30 AM to 1:30 PM. Urine is collected in each clearance period
and analyzed for sodium, osmolality, u-AQP2, u-ENaC-betaCR, u-cAMP, u-PGE2, and 51CrEDTA.
Blood samples will be drawn every 30 min from 9:30 AM to 10:30 AM and every hour from 11:30
AM to 1:30 PM, and will be analyzed for sodium, osmolality, and 51Cr-EDTA. In addition,
analysis of p-AVP, p-Renin, p-ANG II, p-Aldo, p-ANP, and p-BNP will be performed from blood
samples drawn at 10:30 AM, 11:30 AM, 12:30 PM, and 1:30 PM.
Statistics Statistical analyses will be performed using SPSS version 15 (SPSS, Chicago, IL).
Single baseline values are obtained by taking the weighted average of the measurements from
the two baseline periods. The baseline values of the two groups will be compared by Student's
t-test. The baseline values during HS and LS intake will be compared by paired samples
t-tests. The investigators will use the "General Linear Model Repeated Measures" procedure in
SPSS with time as the within-subject factor and group as the between-subject factor to
compare the effect variables in patients and controls. The changes in response to the
hypertonic saline infusion in each group will be analyzed with the General Linear Model
Repeated Measures procedure with time as the within-subject factor and paired samples t-tests
with Bonferroni correction as post hoc tests. P values ≤0.05 will be considered significant.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04310319 -
Wishing to Decrease Aquaresis in ADPKD Patients Treated With a V2Ra; the Effect of Regulating Protein and Salt
|
N/A | |
Completed |
NCT04363554 -
The Kidneys Ability to Concentrate and Dilute Urine in Patients With Autosomal Dominant Polycystic Kidney Disease
|
N/A | |
Recruiting |
NCT05521191 -
A Study of RGLS8429 in Patients With Autosomal Dominant Polycystic Kidney Disease
|
Phase 1 | |
Completed |
NCT03687554 -
Effect of Venglustat in Patients With Renal Impairment
|
Phase 1 | |
Terminated |
NCT03523728 -
A Medical Research Study Designed to Determine if Venglustat Can be a Future Treatment for ADPKD Patients
|
Phase 2/Phase 3 | |
Completed |
NCT00565097 -
Lanreotide as Treatment of Polycystic Livers
|
Phase 2/Phase 3 | |
Completed |
NCT02251275 -
Long Term Safety of Immediate-release Tolvaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease
|
Phase 3 | |
Completed |
NCT01559363 -
A Safety, Pharmacokinetic & Dose-Escalation Study of KD019 in Subjects With Autosomal Dominant Polycystic Kidney Disease
|
Phase 1/Phase 2 | |
Completed |
NCT02903511 -
Feasibility Study of Metformin Therapy in ADPKD
|
Phase 2 | |
Completed |
NCT00456365 -
Effect of Statin Therapy on Disease Progression in Autosomal Dominant Polycystic Kidney Disease (ADPKD)
|
Phase 3 | |
Recruiting |
NCT05510115 -
Feasibility of Study of Empagliflozin in Patients With Autosomal Dominant Polycystic Kidney Disease
|
Phase 2 | |
Completed |
NCT02494141 -
Curcumin Therapy to Treat Vascular Dysfunction in Children and Young Adults With ADPKD
|
Phase 4 | |
Completed |
NCT04407481 -
PErfusioN, OxyGen ConsUmptIon and ENergetics in ADPKD (PENGUIN)
|
||
Completed |
NCT02847624 -
Post-Marketing Surveillance Study of Tolvaptan in Patients With ADPKD
|
||
Completed |
NCT03342742 -
Daily Caloric Restriction and Intermittent Fasting in Overweight and Obese Adults With Autosomal Dominant Polycystic Kidney Disease
|
N/A | |
Completed |
NCT02656017 -
Metformin as a Novel Therapy for Autosomal Dominant Polycystic Kidney Disease
|
Phase 2 | |
Completed |
NCT04023214 -
The Role of Endothelial Dysfunction in Adult Polycystic Kidney Disease
|
||
Terminated |
NCT01589705 -
The Relation Between Uric Acid Level and Endothelial Dysfunction in Patients With Polycystic Kidney Disease
|
N/A | |
Completed |
NCT00426153 -
Octreotide in Severe Polycystic Liver Disease
|
Phase 2/Phase 3 | |
Completed |
NCT04534985 -
Time Restricted Feeding in Autosomal Dominant Polycystic Kidney Disease
|
N/A |